Spanish Capital Cell was one of the first equity crowdfunding platforms that specialised in life sciences and biotech projects in Europe. In March, the group raised more than €1m through funding through the Spanish biotech campaign Bionure a new record. EuroBiotech talked to Capital Cell founder Daniel Oliver about their recent expansion into the UK and the development of the European life sciences crowdfunding scene.
Borreliosis vaccine receives FDA Fast Track Status
Latest NewsFrench vaccines expert Valneva SE announced that the FDA has granted Fast Track designation for its Lyme borreliosis vaccine candidate VLA15.
Crowdfunding: Fuelling EU biotech
OpinionSpanish Capital Cell was one of the first equity crowdfunding platforms that specialised in life sciences and biotech projects in Europe. In March, the group raised more than €1m through funding through the Spanish biotech campaign Bionure a new record. EuroBiotech talked to Capital Cell founder Daniel Oliver about their recent expansion into the UK and the development of the European life sciences crowdfunding scene.
Roche exits epigenetic drug deal
Latest NewsAfter 3 years of collaboration Roche has ended a cancer deal with the Spanish biotech company Oryzon granting the rights to their cancer candidate ORY-1001.
Ablynx adds Sanofi to its list of pharma partners
Latest NewsBelgian nanobody-developer Ablynx NV now also works together with French pharma company Sanofi. The deal is potentially worth €2.4bn but comes with an upfront payment of just €23m. The partners will initially focus on therapeutics for the treatment of various immune-mediated inflammatory diseases.
Shire licensed bispecific antibody from Novimmune
Latest NewsSwiss biopharmaceutical company Novimmune grants pharma company Shire a worldwide license to develop and commercialise a pre-clinical bispecific antibody candidate for haemophilia A.
One cell, many discoveries
ProductsBe ready for the next generation of cell analysis and isolation with BD FACSMelody.
UK invests £86m in healthcare SMEs
Latest NewsThe UK government has set up a new fund to support medical innovation. Breakthrough innovations that have the potential to benefit the NHS will also undergo accelerated access review aimed at speeding up access to novel medicines.
German PEI limits use of daclizumab
Latest NewsFollowing a safety warning of the EMA on deaths related to Biogen’s multiple scleroisis (MS) drug Zinbryta (daclizumab), German regulatory authority has issued a red hand letter.
Microbiome shows COPD subtypes
Latest NewsGerman researchers have found that the lung microbiome is indicative for different subtypes of chronic obstructive pulmonary disease (COPD).
Psoriasis: FDA approves guselkumab
Latest NewsThe Food and Drug Administration has granted US market approval to Janssen Biotech/MorphoSys’ IL23 blocker guselkumab (Temfya) as therapy for moderate to severe psoriasis.